Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized, double blind (3rd party open), placebo-controlled, parallel group, multicentre study to evaluate the multiple dose safety, tolerability, pharmacokinetics and pharmacodynamics, of PF-00868554 in hepatitis C virus (HCV) positive otherwise healthy patient volunteers

Next Previous
X
Search
Trial Profile

A phase 1, randomized, double blind (3rd party open), placebo-controlled, parallel group, multicentre study to evaluate the multiple dose safety, tolerability, pharmacokinetics and pharmacodynamics, of PF-00868554 in hepatitis C virus (HCV) positive otherwise healthy patient volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filibuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 21 Apr 2011 Actual end date changed from May 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 31 Oct 2008 Results were presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 31 Oct 2008 Endpoint 'Viral load' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top